![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LYN-005 (oral weekly risperidone), is being evaluated in phase 3 clinical trials for the treatment of people living with schizophrenia and bipolar 1 disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-005
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
The financing will be used to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems, including LYN-005 (risperidone), being developed for schizophrenia and bipolar I disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-005
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Details:
The net proceeds will support the development of Lyndra’s pipeline, including oral weekly LYN-005 (risperidone), which is near completion of a pivotal phase 3 study and is being developed for the treatment of people living with schizophrenia and bipolar I disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-005
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sarissa Capital
Deal Size: $101.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing December 25, 2023
Details:
Oral weekly LYN-005 (risperidone) is a serotonin and norepinephrine reuptake inhibitor and is being developed for the treatment of people living with schizophrenia and bipolar I disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-005
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: LYN-163
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
LYN-014, Lyndra’s investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD).
Lead Product(s): Levomethadone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-014
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
Data demonstrate LYN-013 delivered sustained buprenorphine drug levels over one-week dosing period and showed sustained suppression of opioid self-administration in an animal model.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-013
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Details:
LYN-005 is Lyndra's oral, ultra-long-acting, extended-release risperidone capsule, in development for the weekly treatment of schizophrenia. Funding will advance Lyndra’s lead product candidate into pivotal trials as the Company prepares for commercialization in the U.S.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-005
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AIG Investments
Deal Size: $60.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 24, 2021
Details:
LYN-014 is designed to address a critical unmet need for people with opioid use disorder and provide consistent target therapeutic levels of levomethadone over the course of an entire week from a single, once-weekly oral capsule.
Lead Product(s): Levomethadone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-014
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
Data demonstrate LYN-005 quickly reaches therapeutic levels in patients, provides sustained risperidone drug levels for repeat one-week dosing intervals and reduces peak drug exposure.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-005
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2021